Meet our Management Team

As CEO, Mr. Gregg is responsible for managing operations for AmbioPharm and serves on the Board of Directors. Prior to AmbioPharm, he had long and successful career at Bachem, a company specializing in the development and manufacture of peptides and oligonucleotides, where he held for 8 years the position of COO for Bachem Americas. In his extensive career at Bachem, Mr. Gregg has held a variety of positions in peptide manufacturing, quality and compliance, and operations management. His skills include driving business and operational growth and strategic acquisition and integration. He holds an MBA from San Diego State University and a BA in Chemistry from the University of California, San Diego.

Mr. Kiel is the Chief Financial Officer of Ambio Pharmaceuticals, the parent company of AmbioPharm. He is also Secretary/Treasurer of the Company and member of the Board since its formation in 2014. He is also primarily responsible for all capital markets activity.
As CFO, Mr. Kiel is responsible for the financial health of the organization, including accounting, financial reporting, cash management, and relations with investors, banks and government. He actively participates in negotiations and contract review,
He was previously a Partner at Deloitte Consulting, one of the nation’s Big Four accounting firms. He holds an MBA from The Ohio State University and was awarded a CPA (now inactive) and Series 7 license.

As Vice President of Global Research and Development, Mr. Zhang is responsible for AmbioPharm’s process development activities at the North Augusta headquarters as well as the Shanghai site. He has more than 20 years’ experience in small- and large-scale peptide synthesis and manufacturing under current Good Manufacturing Practice. Mr. Zhang has expertise with SPPS, LPPS, and hybrid synthesis, successfully employing these approaches for the development of efficient, large-volume commercial peptide manufacturing processes. Additionally, Mr. Zhang establishes synthesis procedures for key building blocks including unnatural amino acids which are not commercially available for inclusion in the manufacture of API peptides. Prior to AmbioPharm, Mr. Zhang spent time at CPC Scientific.

As Vice President of Project Management, Ms. Bridges is responsible for Project Management leadership globally. With 30 years of experience in project management, 15 years in the Pharmaceutical industry, and 6 years in the CDMO industry, she has worked for CDMO leaders such as Corden Pharma and Cambrex. Ms. Bridges is a solution-oriented leader, dedicated to developing strong Project Management systems to meet client program needs and deliver superb customer service in the CDMO space. Ms. Bridges holds a Bachelor of Science degree in Chemical Engineering from Clemson University and was awarded a PMP in 2020.

As Senior Quality & Regulatory Advisor, Brant Zell leads the Quality Assurance organization at AmbioPharm globally. Mr. Zell has over 40 years of Quality and Compliance experience with over 13 years in the peptide API industry. He has dedicated his career in ensuring patient safety and health through setting and demanding appropriate current Good Manufacturing Practice. Prior to AmbioPharm, Mr. Zell oversaw Quality at PolyPeptide Laboratories. Mr. Zell is the one of the founders and chair of the Bulk Pharmaceutical Task Force, a group working directly with FDA leadership and representing the industry view on compliance, GDUFA, best practices, and regulatory concerns. Mr. Zell has a Master of Science in Analytical Chemistry and a Master of Business Administration and Technology Management.

Mr. Gary Hu is Senior Vice President of Sales, responsible for sales and business development in Asia including India. Mr. Hu has more than 30 years of experience in the peptide, oligo, and small molecule CDMO industry. Prior to AmbioPharm, he held various leadership roles in business development, strategic alliances, licensing, sales, marketing, project management, and logistics at American Peptide Company and Bachem. In 2018, Mr. Hu established the Bachem K.K. entity in the pharma cluster of Nihonbashi in Tokyo Japan. He also served as board member of American Peptide Company and Bachem Japan K.K.

Mr. Wen Du brings over 20 years of experience in the biotech and pharmaceutical industry, with deep expertise in supply chain, procurement, manufacturing, and operations across both large pharmaceutical companies and CDMOs. As General Manager of AmbioPharm Shanghai, he oversees site operations and drives strategic growth in alignment with the headquarters’ overall strategy.  
Prior to joining AmbioPharm, Mr. Du spent 6.5 years at Lonza, where he served as Senior Director, Head of Operations for Mammalian Mid-Scale at the Switzerland site. He also held key leadership roles at Lonza’s Guangzhou biologics facility, including Manufacturing Director and Supply Chain Director. Earlier in his career, Mr. Du led supply chain operations at Takeda, serving as Supply Chain Director for the Tianjin site and Head of the China Logistics Center.
Mr. Du holds an MBA from Sun Yat-sen University, a Bachelor’s degree in International Economics and Trade from Hubei University of Technology, and a second Bachelor’s degree in Pharmacy from China Medical University.

Sammi Liu possesses extensive work experience in various finance and HR roles. She joined AmbioPharm in 2013 and progressed from the role of Director of Corporate Finance and Investor Relations to her current position as VP of Finance and HR. Throughout her tenure, she supported the fundraising efforts for series A-1, series A-2, and series B rounds. Currently, she oversees the HR and Finance teams at both North Augusta headquarters and the Shanghai site. Prior to joining AmbioPharm, Ms. Liu worked as a Marketing Specialist at Hang Lung Properties in Shanghai. She holds a Master of Philosophy from Shangdong University, an MBA specialized in Finance from Louisiana State University, and a certificate in Business Analytics from Harvard University.